Currently, pembrolizumab and nivolumab, which target PD-1 receptors, have been approved for the first- and second-line treatment of NSCLC, respectively.[5,14,15] Other PD-1/PD-L1 inhibitors are in various stages of clinical development. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.